PET in breast cancer*

https://doi.org/10.1016/S0001-2998(98)80034-2Get rights and content

Over the past decade, the role of radiology in breast cancer has changed significantly because of the technical advances in mammography, greater use of ultrasonography, and the emergence of magnetic resonance imaging (MRI), as well as development of functional imaging techniques that add new dimensions to the noninvasive evaluation of patients with breast cancer. Currently, radiological evaluation of breast cancer is important not only for early detection of this disease, but also for staging, assessing certain prognostic factors, and monitoring response to treatment. This review focuses on the potential applications and limitations of positron emission tomography (PET) as a functional imaging method in breast cancer. PET with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) has been used successfully in an increasing number of oncological applications and is considered a valuable adjunct to antomical imaging methods, providing unique functional information for better characterization of disease. The contributions of PET to breast cancer imaging can be considered in two main categories. First, by providing qualitative and/or quantitative information, FDG-PET can aid in detection and discrimination of breast cancer in its primary location. Although, FDG-PET is certainly not necessary in every potential case of breast cancer, it can be very useful in clinically and radiologically “difficult-to-examine breasts,” eg, following breast surgery. Qualitative assessment of the extent of the tumor spread provides prognostic information and allows for selection of appropriate therapy. The identification of tumor spread to the axillary nodes or to more remote nodal groups, ie, internal mammary, or supraclavicular nodes, is probably the most practical information that qualitative FDG-PET can offer. Although it is still too early to formulate definite clinical recommendations, it appears likely that FDG-PET has the potential to reduce the number of patients requiring nodal dissection. Second, PEt imaging can provide an assessment of the biological behavior of breast cancer. Quantitative and/or semiquantitative FDG-PET yields valuable information regarding prognosis and response to therapy in a timely fashion. Preliminary studies have indicated that serial assessment of tumor metabolism by FDG-PET early during effective chemohormonotherapy may predict subsequent response to such therapy. The use of PET with the estrogen analogue 16α-[18F]fluoro-17β-estradiol (FES) to monitor receptor function and response to hormonal therapy opens up intriguing new ways to monitor patients with breast cancer at a cellular level

References (58)

  • BrownRS et al.

    Over expression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study

    Cancer

    (1993)
  • XuM et al.

    Local threshold for segmented attenuation correction of PET imaging of the thorax

    IEEE Trans Nucl Sci

    (1994)
  • KubotaK et al.

    Lung tumor imaging by positron emission tomography using C-11 L-methionine

    J Nucl Med

    (1985)
  • ZasadnyK et al.

    Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction

    Radiology

    (1993)
  • AvrilN et al.

    Breast imaging with fluorine-18-FDG PET: quantitative image analysis

    J Nucl Med

    (1997)
  • AvrilN et al.

    Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose

    J Clin Oncol

    (1996)
  • WahlRL et al.

    Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma

    Radiology

    (1992)
  • PatlakCS et al.

    Graphical evaluation of blood-to-brain transfer constant from multiple-time uptake data. Generalization

    J Cereb Blood Flow Metab

    (1985)
  • WahlRL et al.

    Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation

    J Clin Oncol

    (1993)
  • TabarL et al.

    Efficacy of breast cancer screening by age. New results from Swedish two-country trial

    Cancer

    (1995)
  • TseNY et al.

    The application of positron emission tomography with fluorodeoxyglucose to the evaluation of breast disease

    Ann Surg

    (1992)
  • WahlRL et al.

    Primary and metastatic breast carcinoma: initial clinical evaluation with PEt with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose

    Radiology

    (1991)
  • NiewegOE et al.

    Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer

    Cancer

    (1993)
  • ScheidhauerK et al.

    Quantitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability

    Eur J Nucl Med

    (1996)
  • AdlerLP et al.

    Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET

    Radiology

    (1993)
  • HohK et al.

    Cancer detection with whole-body PET using [18F]fluoro-2-deoxy-D-glucose

    J Comput Assist Tomogr

    (1993)
  • KubotaR et al.

    Intratumoral distribution of fluorine-18-deoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiographic comparison with FDG

    J Nucl Med

    (1992)
  • WahlRL et al.

    Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-deoxyglucose-PET

    J Nucl Med

    (1994)
  • HarrisJR et al.

    Cancer of the breast

  • Cited by (102)

    • 16α-[<sup>18</sup>F]-fluoro-17ß-oestradiol ([<sup>18</sup>F]FES): A biomarker for imaging oestrogen receptor expression with positron emission tomography (PET)

      2015, Medecine Nucleaire
      Citation Excerpt :

      In contrast to uterine tissues, human breast cancer [18F]FES uptake does not seem to be affected by exogenous oestradiol administration or other hormonal status variables [40,41]. In human breast cancers, [18F]FES has been used for predicting the response to treatment [42] and for demonstrating the anti-oestrogenic effect of tamoxifen [26]. A metabolic flare resulting in a transient increase in tumour [18F]FDG uptake was sometimes reported in the early days after the onset of endocrine therapy and was usually followed by clinical remission [43].

    • PET and PET-CT Imaging in Treatment Monitoring of Breast Cancer

      2009, PET Clinics
      Citation Excerpt :

      This technique was followed by imaging using monoclonal antibodies against carcinoembryonic antigens and other antigens expressed in breast cancer and imaging with 99mTc-tetrofosmin or 99mTc-sestamibi for primary and recurrent disease.17,18 Since the introduction of positron emission tomography (PET) in clinical oncology, 18F-fluorodeoxyglucose (18F-FDG) PET has been shown to be an effective and accurate imaging modality for staging and restaging of recurrent and metastatic disease and for treatment monitoring.19–22 Sequential 18F-FDG PET imaging has been widely studied as a method for assessing tumor response to neoadjuvant chemotherapy.

    • Positron Emission Tomography/Computed Tomography: The Current Technology and Applications

      2009, Radiologic Clinics of North America
      Citation Excerpt :

      FDG PET has a limited role in the diagnosis of breast cancer,34 but it is important in detecting locoregional (including nodal) and distant disease, in helping to plan surgical and medical treatment, in monitoring response to treatment, and in finding recurrence.35–41 PET also has the potential to evaluate novel treatment agents rapidly by detecting their effects on specific receptors37,42 and has been shown to improve prediction of the clinical outcome in patients who have previously treated breast cancer.43,44 For thyroid cancer, FDG PET is approved for restaging patients who have thyroglobulin-positive, iodine-negative disease.

    View all citing articles on Scopus
    *

    Supported in part by National Cancer Institute grant no. CA48286.

    View full text